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Abstract 
Leukotrienes are potent pro-inflammatory lipid 
mediators derived from arachidonic acid through 
several enzymatic pathways. They have an essential 
role in allergic inflammation, where they induce 
bronchoconstriction, airway edema, and 
chemotaxis of the inflammatory cells in the airways, 
nasal and conjunctival tissues. Leukotriene 
modifiers include leukotriene receptor antagonists 
(montelukast, zafirlukast and pranlukast) and 
leukotriene synthesis inhibitors (zileuton). These 
medications have been extensively used in 
childhood allergic diseases. This review will 
highlight the leukotriene pathway and its role in 
allergy as well as the effects of leukotriene 
modifiers in different allergic disorders. 
 
Allergic inflammation is due to a complex interplay 
between several inflammatory cells, including mast 
cells, basophils, lymphocytes, dendritic cells, 
eosinophils, and sometimes neutrophils. These cells 
produce multiple inflammatory mediators, 
including lipids, purines, cytokines, chemokines, 
and reactive oxygen species. Allergic inflammation 
affects target cells, such as epithelial cells, 
fibroblasts, vascular cells, and airway smooth 
muscle cells, which become an important source of 
inflammatory mediators.
1
 Leukotrienes are potent  
newly formed lipid mediators that are derived from 
arachidonic acid upon cellular activation, including 
IgE receptor cross-binding on mast cell surface.
2 
Leukotrienes (“leuko,” from white blood cells; 
and “trienes,” three conjugated double bonds) 
comprise a family of products of the 5-lipoxygenase 
(5 Lipo-pathway of arachidonic acid metabolism.
3 
They are divided into two classes: the 
chemoattractant LTB4 and the spasmogenic 
cysteinyl leukotrienes [CysLTs: LTC4, LTD4, and 
LTE4] which have been termed previously as slow-
reacting substance of anaphylaxis (SRS-A).
4 
 
Biosynthesis of leukotrienes (figure1) 
The synthesis of leukotrienes from arachidonic acid 
is initiated by 5-lipoxygenase (5-LO) in concert 
with 5-lipoxygenase–activating protein (FLAP). 
Although FLAP does not have enzymatic activity, it 
enhances the ability of 5-LO to interact with its 
substrate.
5 
Arachidonic acid, which is esterified on 
plasma membrane phospholipids, is cleaved by the 
action of different phopsholipase A2 enzymes, 
released and metabolized into LTA4. 
2 
LTA4 is 
converted by LTA4 hydrolase to LTB4, or it can be 
conjugated with reduced glutathione by LTC4 
synthase to yield LTC4. LTB4 and LTC4 are 
exported from the cell by specific transporter 
proteins; the released LTC4 is converted to LTD4 
which undergoes conversion to LTE4 by sequential 
amino acid hydrolysis.
3       
LTA4 is highly reactive, 
with an estimated half-life less than 3 seconds. 
LTC4 and its metabolites, LTD4 and LTE4, are 
known as cysteinyl-LTs due to the common 
cysteine in their side chains.
6
  
The enzyme 5-LO is mainly expressed in 
granulocytes, monocytes, macrophages, mast-cells 
and B lymphocytes.
7
 Mast cells and eosinophils can 
produce large amounts of LTC4 from an 
endogenous pool of arachidonic acid. Human 
bronchial fibroblasts constitutively express 5-LO, 
FLAP, LTA4 hydrolase, and LTC4 synthase and 




Although nonleukocyte cells generally do not 
have sufficient 5-LO and FLAP to synthesize 
appreciable amounts of leukotrienes from 
arachidonate, such cells expressing distal LTA4-
metabolizing enzymes can take up leukocyte-
derived LTA4 and metabolize it into bioactive 
leukotrienes, a process that is termed transcellular 
biosynthesis.
6 
Leukotrienes and cytokines can regulate each 
other; interleukin-13, a product derived from type 2 
helper T (Th2) lymphocytes that participates in the 
development of asthma, can up-regulate both the 
leukocyte biosynthesis of LTD4 and the expression 
of cellular type 1 Cys LT  receptors (CysLT1). 
Moreover, LTD4 can up-regulate production of 
interleukin-13, as well as the expression of its 
receptor. The result of this cross-talk is a self-
perpetuating circuit of inflammation and smooth-
muscle contraction in which interleukin-13 and its 
receptor mediate some of the actions of LTD4, 













Figure 1. The main pathways to the formation of the leukotrienes and the sites of action of the current drug 
groups (in boxes) that can attenuate leukotriene responses (Quoted from O’Donnell SR. Leukotrienes: 
Biosynthesis and mechanisms of actions. Aust Prescr 1999; 22: 55-7. ) 
 
 
Receptors of leukotrienes 
Leukotrienes act by binding to specific heptahelical 
receptors of the rhodopsin class that are located on 
the outer plasma membrane of structural and 
inflammatory cells.
9 
Once ligated by the 
leukotriene, these receptors interact with G proteins 
in the cytoplasm, thereby eliciting increases in 
intracellular calcium and reductions in intracellular 
cyclic AMP. These proximal signals activate 
downstream kinase cascades in ways that alter 




Two G-protein coupled receptor subtypes for 
CysLTs (CysLT1 and CysLT2), that have 38% 
amino acid identity, have been identified. 
10
 The 
CysLT1 and CysLT2 receptors are broadly 
expressed by structural and hematopoietic cells. 
Some cell types (vascular smooth muscle) express 
mostly Cys-LT1 receptors
11
, whereas others 
(endothelial cells) dominantly express CysLT2 
receptors.
12 
 Both receptors are expressed by cells of 
the innate (macrophages, monocytes, eosinophils, 
basophils, mast cells, dendritic cells) and adaptive 
(T and B lymphocytes) immune systems, implying 
potentially cooperative functions in immunity and 
inflammation.
9   
CysLT1 receptor binds LTD4 with high 
affinity and LTC4 with lesser affinity, whereas 
CysLT2 receptor binds both LTC4 and LTD4 with 
equal affinities. Neither receptor exhibits 
substantial affinity for LTE4 in radioligand binding 
assays nor does LTE4 elicit strong signalling 
responses in cells expressing CysLT1 or CysLT2 in 
isolation.
11, 13 
Increased vascular permeability 
induced by LTE4 in mice lacking CysLT1 and 
CysLT2 receptors suggests the existence of a third 
CysLT receptor that responds preferentially to 
LTE4.
14
 Certain reported actions of CysLT are not 
readily explained by either CysLT1 or CysLT2, 
raising the possibility of the presence of CysLT1–
CysLT2 heterodimers or additional receptors.
15
 One 
candidate is G protein–coupled receptor 17 
(GPR17), a dual-uracil nucleotide–CysLT 
receptor.
16 
Two LTB4 receptor subtypes (BLT1 and 
BLT2), that are cell surface G protein-coupled 
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seven transmembrane domain receptors, have been 
identified.  These receptors differ in their affinity 
and specificity for LTB4 and their expression 
pattern. BLT1, a specific high affinity receptor for 
LTB4, is expressed predominantly on leukocytes 
including granulocytes, monocytes, macrophages, 
mast cells, dendritic cells, and effector T cells,
17
 
whereas BLT2, a low affinity receptor which can 
also bind to other eicosanoids, is expressed 




Role of leukotrienes in allergic inflammation  
CysLT1 receptor mediates sustained broncho-
constriction, mucus secretion, and edema in the 
airways (figure 2).
19 
CysLT inhalation in patients 
with asthma increases the number of sputum 
eosinophils and causes recruitment of eosinophils 
into the airway mucosa. 
20
 CysLTs prime progenitor 
cells to differentiate into mature blood cells,  cause 
chemotaxis of eosinophils increasing their cellular 
adhesion and transendothelial migration across the 
vessel wall into the airways,  increase eosinophil 
survival in response to mast cell and lymphocyte 
paracrine signals and  activate eosinophils, mast 
cells, T-lymphocytes, monocytes and basophils. 
21,22 
LTB4 serves as a potent chemoattractant through 
ligation of the high affinity LTB4 receptor-1 
(BLT1) on target cells.
23
 LTB4 can have a central 
role in the neutrophilic inflammation that 
characterises severe asthma and asthma 
exacerbations.
24 
CysLT levels were found to be elevated in 
bronchoalveolar lavage
25
 and induced sputum
26 
from patients with asthma, when compared with 
levels in healthy volunteers at baseline and 
following exercise
27
 or allergen challenge.
28 
In 
patients with allergic rhinitis, specific allergen 
challenge provoked significant increases in nasal 
airway resistance, numbers of neutrophils and 
eosinophils, and levels of protein, histamine, LTB4, 
and CysLTs in nasal lavage fluid.
29
 Also, LTB4 was 
found to cause eosinophil and neutrophil emigration 
into conjunctival tissue. LTB4 and LTC4 levels 
were reported to be increased in the tears of patients 
with seasonal allergic conjunctivitis.
30,31   
Several in vivo and in vitro studies suggest that 
leukotrienes are involved in the inflammation of the 
skin in atopic dermatitis, possibly by chemotaxis of 
inflammatory cells, vasodilatation and oedema, but 
their role is controversial.
32 
The enzymatic activities 
of LTA4 hydrolase in peripheral blood leukocytes 
were found to be associated with disease severity in 
patients with atopic dermatitis and were reduced 







Figure 2. Leukotriene actions on airway structure. 
(Hay DW, Torphy TJ, Undem BJ. Cysteinyl leukotrienes in asthma: old mediators up to new tricks. 
Trends Pharmacol Sci. 1995,16:304-9). 
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Leukotriene modifiers  
Leukotriene modifiers have been available since 
1997 for the treatment of asthma. By modifying 
leukotriene effects, these medications reduce the 
symptoms of allergies, asthma and possibly 
sinusitis and nasal polyps.
34 
Leukotriene modifiers 
are classified in two groups; CysLT1 receptor 
antagonists (LTRAs) – zafirlukast, pranlukast and 
montelukast – block the binding of CysLTs  to  
CysLT1 receptor and thus block the end organ 
response of leukotrienes; and leukotriene synthesis 
inhibitors – zileuton – block the biosynthesis of 
CysLTs.
35 





 which are not FDA 
approved, but they have benefits in early and late 
allergic responses and cold induced asthma.
35  
Montelukast is the most prescribed LTRA in 
Europe and the USA, whereas pranlukast is only 
marketed in Japan and other Asian countries. 
Zafirlukast was the first LTRA that was approved 
in Europe, but it is not frequently prescribed due to 
possible food and drug interactions, and its twice 
daily administration regimen.
38
 Montelukast can be 
used in children from the age of 2 years and has 
been formulated as a chewable, pink, cherry 
flavoured tablet.
39
 The bioavailability is similar 
regardless of patient age, and absorption is not 
affected by food. No drug interactions have been 
documented.
40 
Zafirlukast is approved for the treatment of 
asthma in children aged 7 years or older. It is 
administered orally twice daily and is metabolized 
by the liver; hepatic cytochrome P450 which is 
inhibited by therapeutic concentrations.
41 
Zileuton is 
approved for treatment of persistent asthma in 
patients 12 years or older.
40   
Dosage and route of administration of 
leukotriene modifiers are listed in table 1. 
 
The role of leukotriene modifiers in pediatric 
allergic diseases 
Bronchial asthma 
Two Cochrane Reviews evaluated research 
comparing leukotriene inhibitors with inhaled 
corticosteroids in the management of recurrent and 
persistent asthma in children.
42,43
 In 2002, 
Ducharme and Di Salvio
42
, conducted a 
bibliographic search of randomized controlled 
clinical trials comparing the efficacy of 
antileukotrienes with inhaled corticosteroids (ICSs) 
in asthmatic patients and identified 27 trials of 
which 13 were of high methodological quality. 
Mild-to-moderate chronic asthmatic patients treated 
with LTRAs were 60% more likely to experience 
an asthma exacerbation requiring oral steroids than 
those treated with ICSs (in most trials the daily dose 
of ICSs was 400 mg of beclomethasone or 
equivalent). After 6 weeks of treatment, those 
patients who received ICS showed a significantly 
greater improvement in baseline FEV1, morning 
peak expiratory flow rate, fewer nocturnal 
awakenings and respiratory symptoms, and less use 
of rescue medication.  In 2004, Ng, et 
al
43
 confirmed the earlier findings by Ducharme and 
Di Salvio
42
 that patients on antileukotrienes are 
more likely to suffer an exacerbation requiring 
systemic steroids, to exhibit a lesser improvement 
in lung function, and to report more nocturnal 
awakenings and respiratory symptoms and greater 
use of rescue medication. The available evidence 
convincingly persuades against the use of LTRAs 
as first-line monotherapy in patients with mild-to-
moderate asthma. It must be noted that only 3 of the 
13 studies taken in the meta-analysis were 
conducted among children.
43
 Combination therapy 
is less effective in controlling asthma in children 
with moderate persistent asthma than increasing to 
moderate dose of inhaled glucocorticoids.
44 
Moreover, montelukast has not been demonstrated 
to be an effective inhaled glucocorticoid sparing 
alternative in children with moderate – to - severe 
persistent asthma.
45 
In children with mild persistent 
asthma, montelukast withdrawal can result in 
enhanced airway inflammation, as reflected by 
increased fractional exhaled nitric oxide 




Leukotriene modifiers reduce viral-induced 
asthma exacerbations in young children aged 2-5 
years with intermittent asthma.
47 
Applications of 
leukotriene modifiers that remain under 
investigation are the treatment of persistent 
respiratory symptoms in children after respiratory 
syncytial virus infection
48
 and the treatment of acute 
asthma exacerbations in children.
49 
There are little 
data to suggest a role in acute asthma; small 
investigations demonstrated improvement in PEF 
but clinical relevance requires more study.
50
  
Whether leukotriene modifiers prevent or 
ameliorate airway remodelling in patients with 
asthma is still being tested.
3 
Using lung function 
tests and HRCT image technique, it was found that 
add-on therapy with montelukast improves distal 
lung function reflected by air trapping, but not 




Montelukast and zafirlukast provide protection 
against exercise-induced asthma (EIA) (Evidence 
A). A single oral dose of montelukast is as effective 
as inhaled salmeterol, a long-acting β2 agonist, in 
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preventing EIA.  Its protective effects against EIA 
have been seen to occur as early as 1 hour,
52
 and up 
to 24 hours after a single oral dose.
51
 Moreover, its 
regular use during a 2-month period was not 
associated with the development of tachyphylaxis, 
as occurs with the use of salmeterol.
53
 Also, 
zafirlukast is effective against EIA when 
administered immediately prior to exercise, and a 
single oral dose has been shown to attenuate EIA in 
children.
54 
Leukotirene modifiers are beneficial in patients 
with aspirin-sensitive asthma, a condition in which 
production of very high levels of CysLTs is typical. 
They were more beneficial than placebo in 
improving forced expiratory volume in one second, 
improving symptoms, decreasing exacerbations, 
and providing one more night per week of 
uninterrupted sleep in these patients.
55 
 
Table 1. Dosage and adverse effects of the 







- Children two to 
five years:4 mg 
before bed 
- Children six to 
14 years: 5 mg 
before bed 
- Children ≥ 14 









- Children seven 
to 11 years: 10 mg 
twice daily 
- Patients ≥ 11 













- Patients > 12 
years: 600 mg 









The FDA has approved montelukast for the 
treatment of allergic rhinitis.
40 
Several pivotal 
studies have shown that montelukast was more 
effective than placebo for all nasal and ocular 
symptoms and that there was no significant 
difference between montelukast and loratadine, 
even for nasal obstruction.
56-60
 The combined 
montelukast and cetirizine treatment, when started 6 
weeks before the pollen season, was effective in 
preventing allergic rhinitis symptoms and reduced 
allergic inflammation in the nasal mucosa during 
natural allergen exposure.
61
 In studies carried out on 
patients with seasonal allergic rhinitis and asthma, 
montelukast was found to improve nasal and 
bronchial symptoms. The use of ß-agonists 
(puffs/day) was also reduced with montelukast.
62,63 
LTRAs are modestly better than placebo, as 
effective as antihistamines, but less effective than 
nasal corticosteroids in improving symptoms and 





Oral montelukast for 15 days has been shown to 
produce significant and persistent reduction of 
ocular signs and symptoms in asthmatic patients 
with vernal keratoconjunctivitis.
65
 In seasonal 
allergic conjunctivitis, LTRAs are more efficacious 
than placebo but less efficacious than oral 
antihistamines in adult patients. Clinical trials 
should be conducted to determine whether 
combination treatment with LTRA and oral 
antihistamine has a synergistic effect. Further 
research is required to clarify the role of LTRAs in 
other allergic eye diseases.
66 
Atopic dermatitis 
Because the majority of children with atopic 
dermatitis later develop allergic rhinitis and asthma, 
it is conceivable that early leukotriene modifiers use 
could not only treat atopic dermatitis but also 
modify the disease course of allergic rhinitis and 
asthma in children. However, there are only a few 
small studies of the use of leukotriene modifiers in 
the treatment of atopic dermatitis, most of which 
are case reports.
40 
A significant improvement of 
skin findings in two patients with severe atopic 
dermatitis was reported following treatment with 
oral montelukast at a dose of 10 mg daily for 8 
weeks as a single therapeutic agent.
67 
However, 
another study on the use of either montelukast or 
zafirlukast in seven patients as add-on usage trial in 
atopic dermatitis showed that leukotriene modifiers 
did not lead to a sustained benefit for extensive 
atopic dermatitis.
68
 Therefore, the role of 




Leukotrienes are believed to be involved in the 
pathogenesis of urticaria. Activated mast cells 
generate and release leukotrienes in addition to 
histamine.
69,70
 Available evidence suggests that 
these agents may be useful either as monotherapy 
or add-on therapy in some patients with chronic 




 One subgroup that may respond 
more predictably to these agents is patients with CU 
that is exacerbated by ingestion of aspirin or other 




The therapeutic role of LTA in other allergic 
diseases 
Since inflammatory mediators such as leukotrienes 
have been theorized to play a role in the esophageal 
inflammation noted in patients with eosinophilic 
esophagitis (EoE), leukotriene modifiers may be of 
value for the management of EoE. A small study of 
8 patients with EoE examined the efficacy of the 
leukotriene receptor antagonist, montelukast, and 
found a significant improvement in symptoms in 
the majority of subjects, but no improvement in 
histology.
74
 Leukotriene modifiers have been used 




Response to leukotriene modifiers 
The oral administration of the leukotriene modifiers 
makes them the only class of commonly prescribed 
asthma medications with the potential to undergo 
significant metabolism in the liver, so called “first 
pass effects”. Nonetheless, it has now been shown 
that montelukast demonstrates significant inter-
individual variability in plasma levels.
76 
This 
variability appears to be mediated at least in part via 
the organic anion transporter, OATP2B1, which is 
encoded by the gene SLCO2B1 (solute carrier 
organic anion transporter family, member 2B1). 
Polymorphism in SLCO2B1 gene has been 
associated with variation in plasma montelukast 
levels, with heterozygous individuals demonstrating 
a ~30% reduction in levels versus those harbouring 
the wild type genotype. Clinically, there was 
concordance with the drug level data in that those 
harbouring the variant associated with higher drug 
levels also had a significant improvement in asthma 
symptoms one and six months following the 
initiation of montelukast therapy.
77 
In patients with 
asthma who were treated with a 5-lipoxygenase 
inhibitor, polymorphisms in the promoter of the 5-
lipoxygenase gene (ALOX5) were associated with 
diminished improvement in airflow.
78 
 
Since levels of leukotrienes and their receptors 
are greatly influenced by substances such as 
cytokines, analysis of responsiveness to leukotriene 
modifiers therapy must take into account the genes 
for molecules that reside outside the leukotriene 
pathway.
3 
Also, several patients' characteristics 
affect response to leukotriene modifiers where a 
benefit is more likely in children than in adults
79
 
and in younger than in older children.
80 
Precautions and adverse effects of leukotriene 
modifiers  
LTRAs are generally considered to be safe and well 
tolerated, with headache and gastric discomfort 
being the most common side effects.
7 
Because 
zafirlukast is hepatically metabolized through the 
p450 system, this drug may interfere with the 
metabolism of certain drugs such as warfarin, 
propranolol and theophylline. Other drugs with 
similar metabolism may require serum monitoring. 
Mild gastrointestinal discomfort has been primarily 
reported with zafirlukast compared with 
montelukast. Based on its metabolism, liver 
transaminases should be measured at the start and 
monthly for the first 3 months during zafirlukast 
therapy, and then quarterly.
81
 Approximately 5 
percent of patients receiving zileuton had increases 
in liver enzymes that resolved with 
discontinuation.
82
 The liver enzymes should be 
monitored as with zafirlukast.
40 
An etiologic role for LTRAs in the Churg–
Strauss syndrome is generally excluded.
7
 However, 
a recent analysis of the FDA adverse event 
reporting system database has shown that LTRA 
therapy was a suspect medication in most 
confirmed cases of Churg–Strauss syndrome 
reported.
83
 In the majority of cases treated with a 
LTRA, Churg–Strauss syndrome could not be 




the potential association, the use of LTRAs in more 
severe, steroid-dependent patients should be 
accompanied by intermittent evaluation of blood 
eosinophils.
81 
Based on a limited number of post marketing 
suicide-related adverse experience reports, the FDA 
issued a warning raising concerns about the 
suicidality potential of montelukast and other 
LTRAs.
84 
At present, there is insufficient data to 
prove that there is a link between montelukast and 
suicidality.
85 
In conclusion, leukotrienes play an essential 
role in allergic inflammation and their biosynthesis 
pathway is a target for the drug therapy of allergic 
disorders. Leukotriene modifiers are well tolerated, 
FDA approved medications for asthma and allergic 
rhinitis. Their use in allergic conjunctivitis and 
atopic dermatitis is based on case reports and small 
non-randomized studies which need controlled 
trials for evaluation of their efficacy in these 
disorders. The new discovery about the 
pharmacogenetics of leukotriene pathway offers 
better correlates with the clinical response to 
leukotriene modifiers and targets for new drugs 
inhibiting this pathway. 
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